Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionProduct descriptionProduct information

Dosage forms and strengths

4 evidence topics · 3 sources

Investigational darovasertib tablet and crizotinib capsule in the OptimUM-02 trial
ProductPharmaceutical formRouteMaximum daily dose (mg)
Darovasertib“IDE196 (LXS196)”; “TABLET”“ORAL”“600”
Crizotinib“Crizotinib 200mg hard capsules”; “CAPSULE, HARD”“ORAL”“400”
Darovasertib tablet strengths and commercial formulation

No evidence found.